Josep Tabernero
约瑟普·塔贝内罗
MD, PhD
Head, Department of Medical Oncology; Director, VHIO肿瘤内科主任；VHIO所长
👥Biography 个人简介
Josep Tabernero is one of Europe's most influential oncologists, with a career spanning early drug development, colorectal cancer molecular therapeutics, and leadership of major international clinical trials. He was the lead investigator of the BEACON CRC trial, which established encorafenib plus cetuximab as the new standard of care for BRAF V600E-mutant metastatic colorectal cancer, transforming a historically poor-prognosis subgroup. His broader research program encompasses PI3K/mTOR pathway inhibition, novel targeted agents, and immunotherapy combinations across gastrointestinal malignancies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BEACON CRC — BRAF V600E Targeted Therapy Standard
Led the pivotal BEACON CRC phase III trial demonstrating that encorafenib plus cetuximab significantly improved overall survival and response rate compared with standard chemotherapy in previously treated BRAF V600E-mutant mCRC, establishing this combination as the first approved targeted regimen for this subtype.
PI3K/mTOR Pathway Inhibition in GI Cancers
Conducted extensive early-phase trials characterizing the pharmacodynamics and clinical activity of PI3K, AKT, and mTOR inhibitors in colorectal and other GI cancers, informing rational combination strategies and biomarker selection.
Anti-EGFR Therapy Optimization and Resistance
Published landmark studies on mechanisms of primary and acquired resistance to cetuximab and panitumumab, including the identification of RAS/RAF mutations and HER2 amplification as escape mechanisms, directly influencing clinical management and trial design.
Representative Works 代表性著作
Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC): updated results from a randomised, 3-arm, phase 3 trial
The Lancet Oncology (2021)
Updated analysis confirming superior overall survival (9.3 vs 5.9 months) with encorafenib/cetuximab versus standard chemotherapy in BRAF V600E mCRC, establishing the doublet as the preferred standard regimen.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
New England Journal of Medicine (2009)
Pivotal phase III CRYSTAL trial analysis demonstrating improved response and PFS with cetuximab added to FOLFIRI in KRAS-wildtype mCRC.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 约瑟普·塔贝内罗 的研究动态
Follow Josep Tabernero's research updates
留下邮箱，当我们发布与 Josep Tabernero（Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment